May increased CA125 in borderline ovarian tumor be indicative of a poor prognosis? A case report
暂无分享,去创建一个
L. Frati | P. Benedetti Panici | L. Manganaro | M. Porpora | S. Bernardo | E. Anastasi | I. Pecorella
[1] K. Darcy,et al. Current Approaches and Challenges in Managing and Monitoring Treatment Response in Ovarian Cancer , 2014, Journal of Cancer.
[2] L. Frati,et al. The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer , 2013, Journal of Ovarian Research.
[3] M. Torella,et al. Borderline ovarian tumors: features and controversial aspects. , 2013, European journal of obstetrics, gynecology, and reproductive biology.
[4] L. Frati,et al. HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma , 2012, Tumor Biology.
[5] J. Vidart,et al. Results of the national survey of borderline ovarian tumors in Spain. , 2007, Gynecologic oncology.
[6] C. Zuppan,et al. Best cases from the AFIP: Borderline papillary serous tumor of the right ovary. , 2005, Radiographics : a review publication of the Radiological Society of North America, Inc.
[7] G. Acs. Serous and mucinous borderline (low malignant potential) tumors of the ovary. , 2005, American journal of clinical pathology.